| Similar Articles |
|---|
 |
HBS Working Knowledge
December 21, 2009
Roger Thompson |
Good Banks, Bad Banks, and Government's Role as Fixer In his new book, Too Big to Save, HBS senior lecturer Robert Pozen tells us how to fix the system.   |
The Motley Fool
December 8, 2009
Jennifer Schonberger |
The Economy and the Markets: Where Are We Now? MFS Investment Management chairman Bob Pozen discusses the state of the economy. |
BusinessWeek
March 11, 2010
Geoffrey Miller |
Defusing the Banks' Financial Time Bomb Without tough reforms, writes Robert Pozen, we'll probably face an ugly repeat of recent history. |
The Motley Fool
December 10, 2009
Jennifer Schonberger |
Financial Crises Aren't So Rare. Invest Accordingly. The chairman of MFS Investment Management shares his thoughts on crises -- and our reactions to them. |
HBS Working Knowledge
June 22, 2009
Roger Thompson |
"Too Big To Fail": Reining In Large Financial Firms The federal government should slap tough new regulations on all firms that pose "systemic risk" - the risk that a failure of one institution could wreak havoc across the entire financial system. |
Financial Advisor
December 2004
Tracey Longo |
Getting There From Here A brighter future than the one usually painted for American retirees is possible -- but only with some determination and finesse, says Robert C. Pozen, chairman of the $137 billion Boston-based MFS Investment Management. |
The Motley Fool
January 16, 2008
Brian Orelli |
Headache Almost Over for Pozen The drug is safe; hopefully that's all the FDA wanted to know. |
The Motley Fool
December 11, 2009
Jennifer Schonberger |
How Can We Revive the Securitization Market? Believe it or not, securitized loans made up a larger percentage of lending. Bob Pozen, chairman of MFS Investment Management has a way to revitalize the securitization market. |
BusinessWeek
February 27, 2006
Gene G. Marcial |
Pozen's Trexima: Going To Market With Glaxo Pozen's Trexima is a new drug for severe headaches that analysts claim is more effective and faster-acting than GlaxoSmithKline's $1 billion-a-year blockbuster Imitrex. |
The Motley Fool
December 31, 2009
Jennifer Schonberger |
What's the Best Recipe for Financial Regulatory Reform? Experts give their insight on what's ahead for the industry. In 2010 the U.S. Senate will face the question of how to restructure our financial regulatory system. |
The Motley Fool
June 2, 2004
Roger Nusbaum |
POZEN Is a Poser Here's a great example of the riskiest type of biotech stock. |
Registered Rep.
February 20, 2006
Kevin Burke |
MFS Chairman Blasts Hedge Funds at NICSA Confab The chairman of fund complex MFS Investment Management is calling for the formation of a task force to overhaul performance reporting for hedge funds. |
The Motley Fool
October 8, 2007
Brian Orelli |
Pozen Submits Safety Data Will Pozen's response to its second approvable letter be enough? Investors may want to take this with a grain of salt. |
Investment Advisor
September 2007
Melanie Waddell |
Simplifying Financial Reporting An SEC committee takes the first stab at a huge task under SOX. |
HBS Working Knowledge
July 21, 2010 |
HBS Faculty Debate Financial Reform Legislation What do Harvard Business School faculty experts who conduct research on financial markets and regulation and who, in many cases, have held leadership positions in the financial sector, think about the bill and its intended (and unintended) consequences? |
The Motley Fool
February 24, 2011
Brian Orelli |
Youth in Revolt Against POZEN POZEN fails to get a pediatric extension on its migraine drug. |
Fast Company
Gwen Moran |
5 Ways to Make Your To-Do Lists More Effective Our lists should be derived from our larger goals and include tasks that move us toward those big-picture endeavors, says Robert C. Pozen, author of Extreme Productivity: Boost Your Results, Reduce Your Hours |
The Motley Fool
August 3, 2007
Brian Orelli |
Another Headache for Pozen Investors Drugmaker Pozen might have to run one more trial for the FDA for its migraine drug. |
The Motley Fool
May 17, 2007
Mike Havrilla |
Pozen Poised for Profits The pharmaceutical reported first-quarter results. But investors should look to buy shares of this company because of how its results may look later this year. |
Registered Rep.
October 1, 2006
David A. Geracioti |
Save for Retirement, or Else No matter how you slice it, it's clear that in the future, personal savings will become the most important part of a retirees' income. Recently, Robert Pozen, chairman of MFS Investment Management, described what should be done to fix Social Security and entice workers to save. |
The Motley Fool
May 24, 2011
Jason Moser |
It Pays to Know How Your Money Is Managed A recap of Robert Pozen's new book, The Fund Industry: How Your Money is Managed. |
The Motley Fool
November 26, 2011
Stephanie Baum |
Pozen Inks $75 Million Royalty Deal for Treximet The pharma sells U.S. rights for the migraine drug to Canada's national pension fund. |
